HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Benzoyl peroxide proposal

This article was originally published in The Rose Sheet

Executive Summary

Benzoyl peroxide proposal: FDA extending comment period 60 days for a Feb. 17 proposed rule establishing additional labeling for all topical acne products containing benzoyl peroxide ("The Rose Sheet" Feb. 20, p. 12) to July 17, according to a May 19 Federal Register notice. FDA granted the extension after receiving a request from the Nonprescription Drug Manufacturers Association, which stated that it needed more time due to the "precedent-breaking nature of the agency's proposal," the notice says...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel